CLEARWATER, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported the financial results for its third quarter ended September 30, 2024, updated its financial expectations for the full year ending December 31, 2024, and introduced its financial expectations for the full year ending December 31, 2025.
Recent Financial and Operating Highlights:
“While our Advanced Energy sales decreased year-over-year, we were pleased with the continued resiliency of our disposable handpiece, which grew 9% overall and 15% in the U.S. Looking ahead, we expect the strength of our disposable handpiece sales to continue, and expect to ship a total of nearly 90,000 units for the full year 2024,” said Charlie Goodwin, President and Chief Executive Officer. “It has been a busy few months for us, as we initiated a cost reduction program, raised $7.0 million to strengthen the balance sheet, and amended the covenants with our lender and partner, which we believe will extend our cash runway and allow us to execute our growth strategy.”
Mr. Goodwin continued, “In addition, the Apyx team is in the final stages of developing the Ayon body contouring system, a new product that we believe will dominate the aesthetic surgical space. This system is an all-in-one platform that seamlessly integrates Renuvion, ultrasound-assisted liposuction, power-assisted liposuction, infiltration, aspiration, electrocoagulation and fat transfer into a single, streamlined device. We currently plan to submit a 510(k) for Ayon to the FDA no later than the end of the first quarter of 2025, and, pending approval, launch the system in the back half of 2025.”
In addition, as part of the cost restructuring, Todd Hornsby, Executive Vice President of Sales and Marketing, will be leaving the Company effective immediately.,” stated Mr. Goodwin. “I will be stepping into that role, in addition to my other duties. In order to free up my time, I am pleased to announce Shawn Roman has been promoted from his current position of Vice President Research and Development to Chief Operating Officer. Shawn has been with the Company since 2015 and is well qualified for his new role. ”
The following tables present revenue by reportable segment and geography:
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||||||||
| September 30, | September 30, | |||||||||||||||||||||||||||||||
| (In thousands) | 2024 | 2023 | $ Change | % Change | 2024 | 2023 | $ Change | % Change | ||||||||||||||||||||||||
| Advanced Energy | $ | 9,288 | $ | 9,836 | $ | (548 | ) | (5.6 | )% | $ | 26,507 | $ | 31,248 | $ | (4,741 | ) | (15.2 | )% | ||||||||||||||
| OEM | 2,199 | 2,140 | 59 | 2.8 | % | 7,373 | 6,439 | 934 | 14.5 | % | ||||||||||||||||||||||
| Total | $ | 11,487 | $ | 11,976 | $ | (489 | ) | (4.1 | )% | $ | 33,880 | $ | 37,687 | $ | (3,807 | ) | (10.1 | )% | ||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||||||||
| September 30, | September 30, | |||||||||||||||||||||||||||||||
| (In thousands) | 2024 | 2023 | $ Change | % Change | 2024 | 2023 | $ Change | % Change | ||||||||||||||||||||||||
| Domestic | $ | 7,793 | $ | 8,652 | $ | (859 | ) | (9.9 | )% | $ | 23,459 | $ | 27,660 | $ | (4,201 | ) | (15.2 | )% | ||||||||||||||
| International | 3,694 | 3,324 | 370 | 11.1 | % | 10,421 | 10,027 | 394 | 3.9 | % | ||||||||||||||||||||||
| Total | $ | 11,487 | $ | 11,976 | $ | (489 | ) | (4.1 | )% | $ | 33,880 | $ | 37,687 | $ | (3,807 | ) | (10.1 | )% | ||||||||||||||
Third Quarter 2024 Results:
Total revenue for the three months ended September 30, 2024, decreased to $11.5 million, compared with $12.0 million in the prior year period. Revenue for the Advanced Energy segment decreased to $9.3 million, compared with $9.8 million in the prior year period. OEM segment revenue increased to $2.2 million, compared with $2.1 million for the same period last year. The decrease in Advanced Energy revenue was primarily due to a lower average selling price of generators to domestic customers, fewer domestic customer upgrades to the Apyx One Console and a decrease in international sales of new generators. These decreases were partially offset by an increased volume of single-use handpieces sold domestically and customer upgrades to the Apyx One Console internationally. The increase in OEM segment revenue was due to increased sales volume to existing customers, including Symmetry Surgical, under the Company’s 10-year generator manufacturing and supply agreement. Domestic revenue decreased 10% year-over-year to $7.8 million, and international revenue increased 11% year-over-year to $3.7 million.
Gross profit for the three months ended September 30, 2024, decreased to $7.0 million, compared with $8.0 million in the prior year period. Gross profit margin for the three months ended September 30, 2024 was 60.5%, compared with 66.6% in the prior year period. The decrease in gross profit margins was primarily attributable to a decrease in the average selling price of generators to domestic customers, changes in the sales mix between our two segments, with our OEM segment comprising a higher percentage of total sales and geographic mix within our Advanced Energy segment, with international sales comprising a higher percentage of total sales.
Operating expenses decreased to $10.6 million for the three months ended September 30, 2024, compared with $12.6 million in the prior year period. The decrease in operating expenses was driven by a $1.0 million decrease in salaries and related costs, a $0.5 million decrease in selling, general and administrative expenses, a $0.3 million decrease in research and development expenses and a $0.2 million decrease in professional services expenses.
Other expense, net for the three months ended September 30, 2024 and 2023 was $1.0 million and $0.4 million, respectively. The increase was driven primarily by increased interest expense on higher outstanding borrowings compared to the prior year period.
Income tax expense (benefit) was $0.1 million and $(0.3) million for the three months ended September 30, 2024 and 2023.
Net loss attributable to stockholders was $4.7 million, or $0.14 per share, for the three months ended September 30, 2024, compared with $4.6 million, or $0.13 per share, in the prior year period.
Adjusted EBITDA loss for the three months ended September 30, 2024 and 2023 was $2.4 million and $3.1 million, respectively.
Financial Guidance for Full Year 2024 and 2025:
The Company is updating its financial guidance for the year ending December 31, 2024 to:
The Company is introducing revenue guidance for the year ending December 31, 2025:
Conference Call Details:
Management will host a conference call at 8:00 a.m. Eastern Time on November 8, 2024 to discuss the results of the third quarter, and to host a question and answer session. To listen to the call by phone, interested parties may dial 877-407-9039 (or 201-689-8470 for international callers) and provide access code 13749764. Participants should ask for the Apyx Medical Corporation call. A live webcast of the call will be accessible via the Investor Relations section of the Company’s website (click here) and accessible directly (click here).
An archive of the webcast will be accessible approximately one hour after the live event ends on the Investor Relations section of the Company’s website (click here).
Investor Relations Contact:
Jeremy Feffer, Managing Director LifeSci Advisors
OP: 212-915-2568
This email address is being protected from spambots. You need JavaScript enabled to view it.
About Apyx Medical Corporation:
Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.
Cautionary Statement on Forward-Looking Statements:
Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.
All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to, projections of net revenue, margins, expenses, net earnings, net earnings per share, or other financial items; projections or assumptions concerning the possible receipt by the Company of any regulatory approvals from any government agency or instrumentality including but not limited to the U.S. Food and Drug Administration (the “FDA”), supply chain disruptions, component shortages, manufacturing disruptions or logistics challenges; or macroeconomic or geopolitical matters and the impact of those matters on the Company’s financial performance.
Forward-looking statements and information are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause the Company’s actual results to differ materially and that could impact the Company and the statements contained in this release include but are not limited to risks, uncertainties and assumptions relating to the regulatory environment in which the Company is subject to, including the Company’s ability to gain requisite approvals for its products from the FDA and other governmental and regulatory bodies, both domestically and internationally; the impact of the March 14, 2022 FDA Safety Communication on our business and operations; sudden or extreme volatility in commodity prices and availability, including supply chain disruptions; changes in general economic, business or demographic conditions or trends; changes in and effects of the geopolitical environment; liabilities and costs which the Company may incur from pending or threatened litigations, claims, disputes or investigations; and other risks that are described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and the Company’s other filings with the Securities and Exchange Commission. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.
| APYX MEDICAL CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except per share data) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Sales | $ | 11,487 | $ | 11,976 | $ | 33,880 | $ | 37,687 | ||||||||
| Cost of sales | 4,533 | 3,998 | 13,484 | 12,857 | ||||||||||||
| Gross profit | 6,954 | 7,978 | 20,396 | 24,830 | ||||||||||||
| Other costs and expenses: | ||||||||||||||||
| Research and development | 1,142 | 1,409 | 3,963 | 4,037 | ||||||||||||
| Professional services | 1,648 | 1,831 | 5,318 | 5,165 | ||||||||||||
| Salaries and related costs | 3,508 | 4,534 | 12,886 | 14,329 | ||||||||||||
| Selling, general and administrative | 4,291 | 4,841 | 14,026 | 15,474 | ||||||||||||
| Total other costs and expenses | 10,589 | 12,615 | 36,193 | 39,005 | ||||||||||||
| Gain on sale-leaseback | — | — | — | 2,692 | ||||||||||||
| Loss from operations | (3,635 | ) | (4,637 | ) | (15,797 | ) | (11,483 | ) | ||||||||
| Interest income | 378 | 248 | 1,312 | 478 | ||||||||||||
| Interest expense | (1,431 | ) | (585 | ) | (4,254 | ) | (1,362 | ) | ||||||||
| Other income (expense), net | 24 | (19 | ) | 2 | 622 | |||||||||||
| Total other expense, net | (1,029 | ) | (356 | ) | (2,940 | ) | (262 | ) | ||||||||
| Loss before income taxes | (4,664 | ) | (4,993 | ) | (18,737 | ) | (11,745 | ) | ||||||||
| Income tax expense (benefit) | 60 | (318 | ) | 163 | (2,519 | ) | ||||||||||
| Net loss | (4,724 | ) | (4,675 | ) | (18,900 | ) | (9,226 | ) | ||||||||
| Net loss attributable to non-controlling interest | (21 | ) | (46 | ) | (65 | ) | (120 | ) | ||||||||
| Net loss attributable to stockholders | $ | (4,703 | ) | $ | (4,629 | ) | $ | (18,835 | ) | $ | (9,106 | ) | ||||
| Loss per share: | ||||||||||||||||
| Basic and diluted | $ | (0.14 | ) | $ | (0.13 | ) | $ | (0.54 | ) | $ | (0.26 | ) | ||||
| APYX MEDICAL CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share data) | ||||||||
| September 30, 2024 | ||||||||
| (Unaudited) | December 31, 2023 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 28,013 | $ | 43,652 | ||||
| Trade accounts receivable, net of allowance of $750 and $608 | 13,036 | 14,023 | ||||||
| Inventories, net of provision for obsolescence of $930 and $875 | 9,000 | 9,923 | ||||||
| Prepaid expenses and other current assets | 2,109 | 2,764 | ||||||
| Total current assets | 52,158 | 70,362 | ||||||
| Property and equipment, net of accumulated depreciation and amortization of $3,889 and $3,522 | 1,905 | 1,915 | ||||||
| Operating lease right-of-use assets | 4,820 | 5,162 | ||||||
| Finance lease right-of-use assets | 53 | 69 | ||||||
| Other assets | 1,785 | 1,732 | ||||||
| Total assets | $ | 60,721 | $ | 79,240 | ||||
| LIABILITIES AND EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,914 | $ | 2,712 | ||||
| Accrued expenses and other current liabilities | 7,291 | 9,661 | ||||||
| Current portion of operating lease liabilities | 330 | 347 | ||||||
| Current portion of finance lease liabilities | 20 | 20 | ||||||
| Total current liabilities | 9,555 | 12,740 | ||||||
| Long-term debt, net of debt discounts and issuance costs | 33,853 | 33,185 | ||||||
| Long-term operating lease liabilities | 4,606 | 4,896 | ||||||
| Long-term finance lease liabilities | 38 | 53 | ||||||
| Long-term contract liabilities | 1,271 | 1,246 | ||||||
| Other liabilities | 201 | 198 | ||||||
| Total liabilities | 49,524 | 52,318 | ||||||
| EQUITY | ||||||||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of September 30, 2024 and December 31, 2023 | — | — | ||||||
| Common stock, $0.001 par value; 75,000,000 shares authorized; 34,643,926 issued and outstanding as of September 30, 2024, and 34,643,888 issued and outstanding as of December 31, 2023 | 35 | 35 | ||||||
| Additional paid-in capital | 84,289 | 81,114 | ||||||
| Accumulated deficit | (73,283 | ) | (54,448 | ) | ||||
| Total stockholders’ equity | 11,041 | 26,701 | ||||||
| Non-controlling interest | 156 | 221 | ||||||
| Total equity | 11,197 | 26,922 | ||||||
| Total liabilities and equity | $ | 60,721 | $ | 79,240 | ||||
APYX MEDICAL CORPORATION
RECONCILIATION OF GAAP NET LOSS TO NON-GAAP ADJUSTED EBITDA
(Unaudited)
Use of Non-GAAP Financial Measure
We present the following non-GAAP measure because we believe such measure is a useful indicator of our operating performance. Our management uses this non-GAAP measure principally as a measure of our operating performance and believes that this measure is useful to investors because it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry. We also believe that this measure is useful to our management and investors as a measure of comparative operating performance from period to period. The non-GAAP financial measure presented in this release should not be considered as a substitute for, or preferable to, the measures of financial performance prepared in accordance with GAAP.
The Company has presented the following non-GAAP financial measure in this press release: adjusted EBITDA. The Company defines adjusted EBITDA as its reported net income (loss) attributable to stockholders (GAAP) plus income tax expense (benefit), interest, depreciation and amortization, stock-based compensation expense and other significant non-recurring items.
| Three Months Ended | Nine Months Ended | |||||||||||||||
| (In thousands) | September 30, | September 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Net loss attributable to stockholders | $ | (4,703 | ) | $ | (4,629 | ) | $ | (18,835 | ) | $ | (9,106 | ) | ||||
| Interest income | (378 | ) | (248 | ) | (1,312 | ) | (478 | ) | ||||||||
| Interest expense | 1,431 | 585 | 4,254 | 1,362 | ||||||||||||
| Income tax expense (benefit) | 60 | (318 | ) | 163 | (2,519 | ) | ||||||||||
| Depreciation and amortization | 144 | 186 | 457 | 540 | ||||||||||||
| Stock based compensation | 997 | 1,351 | 3,175 | 4,200 | ||||||||||||
| Gain on sale-leaseback | — | — | — | (2,692 | ) | |||||||||||
| Adjusted EBITDA | $ | (2,449 | ) | $ | (3,073 | ) | $ | (12,098 | ) | $ | (8,693 | ) | ||||
| Last Trade: | US$1.64 |
| Daily Change: | 0.003 0.18 |
| Daily Volume: | 21,882 |
| Market Cap: | US$61.840M |
November 08, 2024 August 08, 2024 May 09, 2024 May 09, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
